Xbrane Biopharma AB Ratios and Metrics

Market cap in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 24, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	211	210	30,743	298	2,258	2,624
Market Cap Growth	-52.20%	-99.32%	10212.77%	-86.80%	-13.94%	58.03%
Enterprise Value	225.42	181.89	30,810	464.18	2,102	2,373
Last Close Price	10.25	10.20	20.10	1250.00	10262.50	13100.00
PE Ratio	-	127.50	-	-	-	-
Forward PE	-	2.45	18.40	27.74	13.18	20.01
PS Ratio	2.54	1.38	207.58	1.25	39.19	245.04
PB Ratio	0.39	0.37	147.42	1.74	5.31	6.08
P/TBV Ratio	35.28	0.64	8.09	82.62	6.50	6.47
EV/Sales Ratio	2.71	1.19	208.04	1.94	36.49	221.63
Debt / Equity Ratio	0.01	0.10	0.46	0.91	0.07	0.08
Net Debt / Equity Ratio	0.03	-0.05	0.32	0.97	-0.37	-0.58
Net Debt / EBITDA Ratio	-0.22	3.98	-1.10	-0.56	1.02	1.42
Net Debt / FCF Ratio	-0.11	0.11	-0.50	-0.40	0.76	1.01
Asset Turnover	0.13	0.20	0.20	0.36	0.08	0.03
Inventory Turnover	0.42	0.28	0.10	2.59	0	-
Quick Ratio	0.71	1.88	0.29	0.31	1.02	1.57
Current Ratio	3.19	7.12	1.13	1.41	2.17	2.55
Return on Equity (ROE)	-13.46%	-12.00%	-74.40%	-108.02%	-39.34%	-53.15%
Return on Assets (ROA)	-9.72%	-3.92%	-14.16%	-44.15%	-22.14%	-45.38%
Return on Invested Capital (ROIC)	-11.68%	-7.34%	-34.53%	-97.84%	-67.84%	-174.91%
Return on Capital Employed (ROCE)	-10.99%	-6.12%	-30.79%	-75.99%	-33.09%	-95.63%
Earnings Yield	-	0.78%	-	-	-	-
Buyback Yield / Dilution	97.34%	0.00%	-246.95%	-2215.66%	-8.38%	-30.25%
Total Shareholder Return	97.34%	0.00%	-246.95%	-2215.66%	-8.38%	-30.25%